Welcome to our dedicated page for Vera Therapeutics SEC filings (Ticker: VERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vera Therapeutics, Inc. (Nasdaq: VERA) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a late clinical-stage biotechnology company focused on serious immunological diseases, Vera Therapeutics uses SEC filings to report clinical milestones, financing transactions, governance changes, and other material events that can be important for investors analyzing VERA stock.
Current reports on Form 8-K feature prominently in Vera Therapeutics’ filing history. For example, the company has filed 8-Ks describing entry into a Sales Agreement with TD Securities (USA) LLC for potential at-the-market offerings of Class A common stock, the pricing of underwritten public offerings of Class A common stock, and the termination of a prior sales agreement. Other 8-Ks report clinical and regulatory updates, such as ORIGIN Phase 3 trial data for atacicept in immunoglobulin A nephropathy (IgAN), including reductions in proteinuria and safety outcomes, as well as the submission of a Biologics License Application and subsequent communications around FDA review.
Filings also cover corporate governance and compensation. Vera Therapeutics has reported the appointment of new directors, including committee assignments and equity compensation under its non-employee director compensation policy, and changes in executive roles such as the departure of its Chief Legal Officer. Additional disclosures describe inducement equity awards granted under the company’s 2024 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4).
Alongside 8-Ks, investors can access registration statements and prospectus supplements referenced in the filings, which relate to public offerings and shelf registration on Form S-3. These documents outline the terms under which Vera Therapeutics may issue Class A common stock to fund its development programs, including atacicept, VT-109, and MAU868.
On Stock Titan, Vera Therapeutics’ SEC filings are updated in near real time from EDGAR. AI-powered summaries help explain the key points of lengthy documents, highlighting items such as clinical trial disclosures, financing capacity, director and officer changes, and at-the-market sales arrangements. Users can quickly scan which filings relate to clinical data, capital raising, or governance, and then drill down into the full text when more detail is needed.
For those tracking insider and equity-related activity, the filings page complements Forms 4 and other ownership reports by surfacing information on option grants, RSUs, and inducement awards described in 8-Ks. Together, these materials provide a detailed view of how Vera Therapeutics structures incentives and finances its late-stage development efforts in immunology and nephrology.
Vera Therapeutics president and CEO Marshall Fordyce reported a mandated sale of 16,925 shares of Class A common stock. The shares were sold in open-market "sell-to-cover" transactions solely to satisfy tax withholding obligations tied to vesting restricted stock units.
The weighted-average sale price was
Vera Therapeutics Chief Operating Officer David Lee Johnson reported an open-market sale of 2,579 shares of Class A common stock at a weighted-average price of $41.9839 per share. After this transaction, he directly owned 45,727 shares.
According to the disclosure, the shares were sold solely to cover tax withholding obligations triggered by the vesting of restricted stock units under the company’s equity incentive plans. The sale was mandated by the company’s sell-to-cover election and is described as not a discretionary trade by the executive.
Vera Therapeutics, Inc. Chief Regulatory Officer William D. Turner reported an open-market sale of 2,187 shares of Class A common stock at a weighted-average price of $41.9839 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations from vesting restricted stock units under the company’s equity incentive plans and did not represent a discretionary trade by Turner. The trades to satisfy withholding occurred over two business days, from February 23 to February 24, 2026. After these transactions, Turner beneficially owned 45,313 shares of Class A common stock.
Vera Therapeutics Chief Commercial Officer Laurence Matthew Skelton reported an open-market sale of 1,582 shares of Class A common stock. The shares were sold on February 23, 2026 at a weighted-average price of 41.9839 per share to satisfy tax withholding obligations from vesting restricted stock units.
The sale was executed under the company’s equity incentive plans as a mandated “sell-to-cover” transaction and was not a discretionary trade by Skelton. After this sale, he beneficially owned 64,218 shares of Vera Therapeutics Class A common stock.
Morgan Stanley Smith Barney LLC submitted a Rule 144 notice to sell 1,800 common shares of VERA.
The filing lists the shares as restricted stock vesting under a registered plan with a vesting/transaction date of
Morgan Stanley Smith Barney LLC submitted a Rule 144 notice to sell 2,600 shares of common stock of VERA (listed on NASDAQ). The sale is tied to restricted stock vesting under a registered plan with an effective date of
VERA submitted a Form 144 notice for a proposed sale of 5,700 shares of common stock tied to restricted stock vesting under a registered plan, dated 02/20/2026. The filing appears on or about 02/23/2026 and references NASDAQ.
Morgan Stanley Smith Barney LLC reported the sale of 2,500 restricted common shares under a registered plan, with the transaction dated
Reporting notification to sell
The filing describes the shares as restricted stock vesting under a registered plan and identifies the transaction as an issuer‑related sale; cash‑flow treatment and sale timing are not detailed in the excerpt.
VERA submitted a Rule 144 notice to sell 16,600 common shares. The filing lists Morgan Stanley Smith Barney LLC as broker and describes the shares as restricted stock vesting under a registered plan, with a transaction date of 02/20/2026 and a filing date shown as 02/23/2026.